Yoshihiko Taniguchi1, Akihiro Tamiya2, Syun-Ichi Isa3, Kenji Nakahama2, Kyoichi Okishio3, Takayuki Shiroyama4, Hidekazu Suzuki4, Takako Inoue5, Motohiro Tamiya5, Tomonori Hirashima4, Fumio Imamura5, Shinji Atagi3. 1. Departments of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan yoshi-taniguchi@kch.hosp.go.jp. 2. Departments of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan. 3. Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan. 4. Department of Thoracic Oncology, Osaka Habikino Medical Center, Habikino, Japan. 5. Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Abstract
BACKGROUND: Nivolumab has shown promising effects in patients with non-small-cell lung cancer (NSCLC) as a second- or later-line treatment. This study aimed to identify patients who would not experience any benefit from nivolumab treatment. MATERIALS AND METHODS: In this study, data for 201 patients treated with nivolumab during 17 December 2015 to 31 July 2016 at three respiratory medical centers in Japan were retrospectively reviewed. We collected clinical data at the time of nivolumab treatment commencement. We investigated the relationship between progression-free survival (PFS) and patient characteristics. RESULTS: In both univariate and multivariate analysis, performance status (PS) score ≥2, steroid use at baseline and lactate dehydrogenase (LDH) level >240 IU/l were significantly associated with poor PFS (all p<0.05). CONCLUSION: PS score ≥2, steroid use at baseline and a high LDH level were predictive of poor PFS in patients with NSCLC treated with nivolumab. Careful monitoring is recommended for treating such patients with nivolumab (UMIN-ID: UMIN000025908). Copyright
BACKGROUND:Nivolumab has shown promising effects in patients with non-small-cell lung cancer (NSCLC) as a second- or later-line treatment. This study aimed to identify patients who would not experience any benefit from nivolumab treatment. MATERIALS AND METHODS: In this study, data for 201 patients treated with nivolumab during 17 December 2015 to 31 July 2016 at three respiratory medical centers in Japan were retrospectively reviewed. We collected clinical data at the time of nivolumab treatment commencement. We investigated the relationship between progression-free survival (PFS) and patient characteristics. RESULTS: In both univariate and multivariate analysis, performance status (PS) score ≥2, steroid use at baseline and lactate dehydrogenase (LDH) level >240 IU/l were significantly associated with poor PFS (all p<0.05). CONCLUSION: PS score ≥2, steroid use at baseline and a high LDH level were predictive of poor PFS in patients with NSCLC treated with nivolumab. Careful monitoring is recommended for treating such patients with nivolumab (UMIN-ID: UMIN000025908). Copyright
Authors: Mitchell S von Itzstein; Amrit S Gonugunta; Helen G Mayo; John D Minna; David E Gerber Journal: Cancer J Date: 2020 Nov/Dec Impact factor: 2.074